ConductScience.org, home

Paper41340907

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effects of Single and Multiple Oral Doses of ABP-671 in Healthy and Hyperuricemic Subjects.

Gurwith M and 4 others. Drug Des Devel Ther, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effects of Single and Multiple Oral Doses of ABP-671 in Healthy and Hyperuricemic Subjects. Papers, record 41340907. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41340907

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effects of Single and Multiple Oral Doses of ABP-671 in Healthy and Hyperuricemic Subjects.
PubMed
Journal
Drug Des Devel Ther
PubMed
Year
2025
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase I
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-12-26
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gurwith MMarc
2Wu RJRoy J
3Schwertschlag UUllrich
4Jin AWAdam W
5Shi DDongfang

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Food-Drug InteractionsMajor topic
HyperuricemiaMajor topic
Humans
Administration, Oral
Male
Adult
Female
Cross-Over Studies
Middle Aged
Dose-Response Relationship, Drug
Healthy Volunteers
Young Adult
Double-Blind Method
Uric Acid

Source PubMed

Download CSV of topics

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132541923Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.Nat Rev Rheumatol2020https://conductscience.org/library/papers/32541923PubMed
230334639
Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
Mod Rheumatol2019https://conductscience.org/library/papers/30334639PubMed
330915866Safety and tolerability of available urate-lowering drugs: a critical review.Expert Opin Drug Saf2019https://conductscience.org/library/papers/30915866PubMed
434907116Update on gout management: what is old and what is new.Curr Opin Rheumatol2022https://conductscience.org/library/papers/34907116PubMed
526907620Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.J Pharmacol Exp Ther2016https://conductscience.org/library/papers/26907620PubMed
634035002EULAR recommendations for intra-articular therapies.Ann Rheum Dis2021https://conductscience.org/library/papers/34035002PubMed
7323903062020 American College of Rheumatology Guideline for the Management of Gout.Arthritis Rheumatol2020https://conductscience.org/library/papers/32390306PubMed
834754317Recent Updates of Natural and Synthetic URAT1 Inhibitors and Novel Screening Methods.Evid Based Complement Alternat Med2021https://conductscience.org/library/papers/34754317PubMed
928744099Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.Drug Des Devel Ther2017https://conductscience.org/library/papers/28744099PubMed
1033926357Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.Expert Opin Pharmacother2021https://conductscience.org/library/papers/33926357PubMed
1129547895Gout: state of the art after a decade of developments.Rheumatology (Oxford)2019https://conductscience.org/library/papers/29547895PubMed
1227380294Gout.Ann Intern Med2016https://conductscience.org/library/papers/27380294PubMed
1331056705URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.Rheumatology (Oxford)2019https://conductscience.org/library/papers/31056705PubMed
1431889230Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects.Clin Exp Nephrol2020https://conductscience.org/library/papers/31889230PubMed
1534216576A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications.Eur J Pharmacol2021https://conductscience.org/library/papers/34216576PubMed
1625567367Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.AAPS J2015https://conductscience.org/library/papers/25567367PubMed
1734862252Pharmacokinetics, Mass Balance, and Metabolism of the Novel Urate Transporter 1 Inhibitor [14C]HR011303 in Humans: Metabolism Is Mediated Predominantly by UDP-Glucuronosyltransferase.Drug Metab Dispos2022https://conductscience.org/library/papers/34862252PubMed
1827980008The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout.J Rheumatol2017https://conductscience.org/library/papers/27980008PubMed
1927112094Gout.Lancet2016https://conductscience.org/library/papers/27112094PubMed
2026170627Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.Drug Des Devel Ther2015https://conductscience.org/library/papers/26170627PubMed

See all 22 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
SLC22A12116085PubTator's text mininghttps://conductscience.org/library/genes/116085

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41340907

GET https://conductscience.org/api/papers/v1/41340907/references?page=2